Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study
Summary: Preclinical studies suggest synergistic effects between androgen receptor inhibitors and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. This phase 2 trial (NCT05223582) evaluates neoadjuvant fuzuloparib plus abiraterone in 35 treatment-naive men with localized high-risk pr...
Збережено в:
| Автори: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2025-03-01
|
| Серія: | Cell Reports Medicine |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2666379125000916 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|